Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.

Acta biomaterialia - 15 Mar 2024

Song Huiling, Li Haosheng, Shen Xiaonan, Liu Kuai, Feng Haoran, Cui Jiahua, Wei Wei, Sun Xiaolu, Fan Qiong, Bao Wei, Zhou Haiyan, Qian Liheng, Nie Huizhen, Cheng Xi, Du Zixiu

Abstract excerpt

Cetuximab (Cet) and oxaliplatin (OXA) are used as first-line drugs for patients with colorectal carcinoma (CRC). In fact, the heterogeneity of CRC, mainly caused by K-ras mutations and drug resistance, undermines the effectiveness of drugs. Recently, a hydrophobic prodrug, (1E,4E)-6-((S)-1-(isopentyloxy)-4-methylpent-3-en-1-yl)-5,8-dimethoxynaphthalene-1,4‑dione dioxime (DMAKO-20), has been shown to undergo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Hydrogen-Ion Concentration

Share to Mutation

Share to Oxaliplatin

Source

Identifiers

PMID: 38331131
DOI: 10.1016/j.actbio.2024.01.047

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pH-responsive cetuximab-conjugated DMAKO-20 nano-delivery system for overcoming K-ras mutations and drug resistance in colorectal carcinoma.PMID 38331131Read ↗

Nanomedicine Strategies to Overcome Multi-Drug Resistance in Cancer: Innovations in Targeted Delivery, Tumor Microenvironment Modulation and Synergistic TherapiesSemantic proximity Read ↗

Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma.Semantic proximity Read ↗

Liver-Specific Nanoparticle-Mediated Delivery and MMP-Triggered Release of Veratridine, a Potent Pro-Apoptotic Molecule, to Effectively Target Metastatic Colorectal CancerSemantic proximity Read ↗

A super-assembled synergistically nanoplatform AP@ZIF-8 Pt for hepatocarcinoma therapySemantic proximity Read ↗

Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer CellsSemantic proximity Read ↗

A CDDP-Cross-Linked Nanoprodrug for Combination Therapy Based on Dual-Augmented Cascade ReactionsSemantic proximity Read ↗

Nanoparticle-based drug delivery systems: What can they really do in vivo?Semantic proximity Read ↗

Tumor Microenvironment-Responsive CA@ZIF-8/MnO 2 Nanoreactor for Self-Reinforcing Cascade Chemodynamic Therapy and ImmunomodulationSemantic proximity Read ↗

Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.Semantic proximity Read ↗

Red Blood Cell-derived Extracellular Vesicles enable Cisplatin and Cetuximab combined Therapy against Triple-Negative Breast CancerSemantic proximity Read ↗

Effective Degradation of Wild-Type and Mutant EGFR Using Self-Assembling Peptide-Derived PROTAC Nanoparticles (NanoTACs) for Cancer Therapy.Semantic proximity Read ↗

Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.